ClinicalTrials.gg
CompletedNCT04474405Updated Sep 25, 2020Results posted

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

An Early Phase 1 interventional study of Flortaucipir F18 and Brain PET Scan in Alzheimer Disease, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Early Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 6 years 10 months after the study started (first participant enrolled Aug 2013, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
14th of 22
36 · median 70
Started
2013
with 2 others
Phase 1
10 of 22
2 open now
Registered
20th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 14th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 1, and was the 20th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers had an (MMSE) score of ≥ 29;
  • MCI due to Alzheimer's disease (AD) consistent with National Institute on Aging (NIA)-Alzheimer's Association working group's on diagnostic guidelines for AD (Alzheimer's Dementia 7:270-9, 2011)
  • Possible or probable AD: Met clinical criteria for possible or probable AD based on the NIA-Alzheimer's Association working group's on diagnostic guidelines for AD (Alzheimer's Dementia 7:263-9, 2011)

Exclusion criteria

Exclusion Criteria:

  • Current psychiatric disease.
  • Evidence of structural abnormalities such as major stroke or mass on MRI that would have made a diagnosis of impairment due to AD unlikely or was likely to interfere with interpretation of a PET scan on MRI.
  • Claustrophobic or otherwise unable to tolerate the imaging procedure.
  • Current clinically significant cardiovascular disease or clinically significant abnormalities on screening (including, but not limited to, interval >450 msec).
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • History of alcohol abuse or substance abuse or dependence
  • Female subjects of who were not surgically sterile, not refraining from sexual activity or not using reliable methods of .
  • Required medications with a narrow therapeutic window
  • Received a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to imaging session
  • Receiving any medications or had participated in a trial with investigational medications within the last 30 days
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Brain flortaucipir PET scan

    Subjects receiving a brain PET scan after flortaucipir administration

    Drug: Flortaucipir F18 · Procedure: Brain PET Scan · Drug: Florbetapir F 18 · Procedure: Brain MRI

  • Experimental
    Whole body flortaucipir PET scan

    Subjects receiving a whole body PET scan after flortaucipir administration

    Drug: Flortaucipir F18 · Procedure: Whole body PET scan

  • Other
    MRI and Amyloid Extension Cohort

    Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)

    Procedure: Brain PET Scan · Drug: Florbetapir F 18 · Procedure: Brain MRI

Interventions

  • IV injection, 370 MBq (10 mCi), single dose

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid

  • ProcedureBrain PET Scan

    positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).

  • ProcedureWhole body PET scan

    positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours

  • IV injection, 370 MBq (10 mCi), single dose

    Also known as: Amyvid

  • ProcedureBrain MRI

    Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain

06

What researchers measure

Primary outcomes

  1. Brain Flortaucipir Uptake

    Brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVr), normalized to the entire cerebellum. A global cortical average volume of interest (VOI) is the average SUVr of the occipital cortex, parietal cortex, and temporal cortex. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: 80-100 minutes postdose

  2. Flortaucipir Whole Body Effective Dose

    Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model.

    Time frame: injection to 6 hours postdose

Secondary outcomes

  1. Flortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam)

    Spearman's correlations between flortaucipir SUVr and cognitive function as measured on the Mini-Mental State Examination (MMSE). MMSE is a 30-point questionnaire that is used to measure cognitive impairment. 0 is the lowest score and 30 is the highest score, indicating normal cognitive function. Lower MMSE scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

    Time frame: at baseline

  2. Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test)

    Spearman's correlations between flortaucipir SUVr and cognitive function as measured on Digit Symbol Substitution Test (DSST). The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. Scores range from 0 to 133. Lower DSST scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

    Time frame: at baseline

  3. Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale)

    Spearman's correlations between flortaucipir SUVr and cognitive function as measured on a Modified Alzheimer's Disease Assessment Scale (ADAS)-Cognitive subscale (including orientation, verbal memory, language, and praxis, minus the spoken language assessment). Scores on the modified scale can range from 0 to 65. Higher scores indicate worsening cognitive function. For this analysis, positive correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and negative correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

    Time frame: at baseline

07

Results

Posted Sep 25, 2020

Participant flow

Enrollment occurred between Aug and Dec 2013. Subjects in the MRI and Amyloid Extension cohort received flortaucipir brain PET scans in Study T807000 (NCT01733355)

Participant flow — Overall Study
MilestoneBrain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension Cohort
Started4354137
Flortaucipir pet scan434490
Florbetapir pet scan430404
Completed434497
Not completed001040
Withdrew: Withdrawal by subject001010
Withdrew: Other000030

Outcome measures

PrimaryBrain Flortaucipir Uptake

Brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVr), normalized to the entire cerebellum. A global cortical average volume of interest (VOI) is the average SUVr of the occipital cortex, parietal cortex, and temporal cortex. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
80-100 minutes postdose
Reported as:
Mean · standardized uptake value ratio (SUVr)
Brain Flortaucipir Uptake
standardized uptake value ratio (SUVr)Brain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)
Brain Flortaucipir Uptake1.780 ± 0.8571.317 ± 0.1611.128 ± 0.0471.107 ± 0.175
PrimaryFlortaucipir Whole Body Effective Dose

Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model.

Time frame:
injection to 6 hours postdose
Reported as:
Mean · mSv/MBq
Flortaucipir Whole Body Effective Dose
mSv/MBqWhole Body Flortaucipir PET Scan
Flortaucipir Whole Body Effective Dose0.0241 ± 0.00160
SecondaryFlortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam)

Spearman's correlations between flortaucipir SUVr and cognitive function as measured on the Mini-Mental State Examination (MMSE). MMSE is a 30-point questionnaire that is used to measure cognitive impairment. 0 is the lowest score and 30 is the highest score, indicating normal cognitive function. Lower MMSE scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

Time frame:
at baseline
Reported as:
Number · correlation coefficient
Flortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam)
correlation coefficientAll Subjects/Brain PET
Flortaucipir PET Correlations With Cognitive Assessments (Mini-mental State Exam)-0.404 (-0.706 to 0.044)
SecondaryFlortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test)

Spearman's correlations between flortaucipir SUVr and cognitive function as measured on Digit Symbol Substitution Test (DSST). The DSST is sensitive to the presence of cognitive dysfunction as well as to change in cognitive function. Scores range from 0 to 133. Lower DSST scores indicate worsening cognitive function. For this analysis, negative correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and positive correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

Time frame:
at baseline
Reported as:
Number · correlation coefficient
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test)
correlation coefficientAll Subjects/Brain PET
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Digit Symbol Substitution Test)-0.273 (-0.744 to 0.403)
SecondaryFlortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale)

Spearman's correlations between flortaucipir SUVr and cognitive function as measured on a Modified Alzheimer's Disease Assessment Scale (ADAS)-Cognitive subscale (including orientation, verbal memory, language, and praxis, minus the spoken language assessment). Scores on the modified scale can range from 0 to 65. Higher scores indicate worsening cognitive function. For this analysis, positive correlation values indicate that higher flortaucipir uptake is associated with decreasing cognitive function and negative correlation values indicate that lower flortaucipir uptake is associated with better cognitive function. 95% confidence interval uses a Fisher's z transformation.

Time frame:
at baseline
Reported as:
Number · correlation coefficient
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale)
correlation coefficientAll Subjects/Brain PET
Flortaucipir PET Correlations With Cognitive Assessments Cognitive Assessments (Alzheimer's Disease Assessment Scale)0.220 (-0.447 to 0.719)
Post-hocFlortaucipir Whole Body Effective Dose With Urine Radioactivity

Radiation dose estimates measured in millisieverts per megabecquerel (mSv/MBq) for the whole body obtained from Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM) radiation dosimetry code. Results calculated using 73.7-kg man model and accounting for total integrated radioactivity excreted in the urine collected in Study A15 (NCT02336360)

Time frame:
injection to 6 hours postdose
Reported as:
Mean · mSv/MBq
Flortaucipir Whole Body Effective Dose With Urine Radioactivity
mSv/MBqWhole Body Flortaucipir PET Scan
Flortaucipir Whole Body Effective Dose With Urine Radioactivity0.0235 ± 0.0016

Adverse events

Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brain PET Scan (AD Subjects)0/4 (0%)0/4 (0%)0/4 (0%)
Brain PET (MCI Subjects)0/3 (0%)0/3 (0%)0/3 (0%)
Brain PET (YCN Subjects)0/4 (0%)0/4 (0%)1/4 (25%)
Brain PET (OCN Subjects)0/4 (0%)0/4 (0%)0/4 (0%)
Whole Body PET Scan0/9 (0%)0/9 (0%)3/9 (33.3%)
MRI and Amyloid Extension Cohort0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent other events
Most frequent other events
EventBrain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension Cohort
diarrhoeaGastrointestinal disorders0/40/31/40/40/90/4
headacheNervous system disorders0/40/30/40/42/90/4
musculoskeletal discomfortMusculoskeletal and connective tissue disorders0/40/30/40/41/90/4

Baseline characteristics

Baseline demographics analysis includes subjects receiving a florbetapir or a flortaucipir PET scan in the study.

Age, Continuous
Age, Continuous(years)Brain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension CohortTotal
Mean68.0 ± 7.8778.7 ± 2.8927.5 ± 2.0866.3 ± 0.5056.3 ± 4.4273.0 ± 13.0960.1 ± 16.52
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Brain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension CohortTotal
Female21133111
Male22316216
Unknown0000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension CohortTotal
American Indian or Alaska Native0000000
Asian0041308
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000101
White43035318
More than one race0000000
Unknown or Not Reported0000011
Region of Enrollment
Region of Enrollment(Participants)Brain PET Scan (AD Subjects)Brain PET (MCI Subjects)Brain PET (YCN Subjects)Brain PET (OCN Subjects)Whole Body PET ScanMRI and Amyloid Extension CohortTotal
United States43449428
08

Study locations

2 sites
  • WCCT Global, LLC
    Cypress, California 90630, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Dec 2013, 3 months.

Results were first posted in Sep 2020, 6 years 9 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 3 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2020
First posted
Jul 16, 2020
StartActual
Aug 16, 2013
Primary completionActual
Dec 9, 2013
CompletionActual
Dec 9, 2013
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04474405
Responsible party
Sponsor
First posted
Jul 16, 2020
Start date
Aug 16, 2013
Primary completion
Dec 9, 2013
Completion
Dec 9, 2013
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Medical Director
study director · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Flortaucipir · Florbetapir

Start the discussion